The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

DSM has entered into negotiations with Adare Pharma Solutions to acquire Adare Biome, a developer and manufacturer of postbiotics, for an enterprise value of €275 million. Adare Biome's origins date back to 1907 when French chemist Pierre Boucard launched Lactéol, a supplement for relieving gut troubles. Available over the counter in 35 countries, Lactéol is said to be "one of the most scientifically well-documented microorganism-based therapeutics in the world in terms of efficacy and safety". DSM hopes to expand the availability of the supplement through its business-to-consumer unit, i-Health. In addition, the ingredients giant plans to further develop Adare Biome's postbiotic business-to-business ingredient, while leveraging its potential in dietary supplements, early life and medical nutrition, and nutritional improvement for the under-nourished. Tom Sellig, CEO of Adare Pharma Solutions, commented: "DSM would be the ideal company to take Adare Biome to a new level and realise the growth potential of postbiotics. They have the infrastructure and strong commercialisation and science capabilities to scale the significant scientific research achieved over the years, and DSM's mission to create healthier lives for all will resonate strongly with the team." Philip Eykerman, DSM's executive vice president health, nutrition & care, said: "Adare Biome would be a perfect fit for DSM, with pioneering science that will complement each of our three businesses. The Adare Biome team will greatly help in accelerating our 'health from the gut' strategy as there is considerable untapped potential for next-generation biotics to support the health of people and animals." The transaction remains subject to consultation with the workers council and customary regulatory conditions.